Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 5/20 | 0.41 |
| ▸ | RXRB | P28702 | 5/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | DRD4 | P21917 | 5/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.36 |
| ▸ | HRH2 | P25021 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181612 | 0.95 | MAPK1 (0.46) | MAPK1RXRARXRBDRD2DRD4 | |
| SCHEMBL2292267 | 0.86 | ELANE (0.37) | MAPK1RXRARXRBDRD2HRH1 | |
| SCHEMBL2293203 | 0.80 | MAPK1 (0.56) | MAPK1RXRARXRBDRD2DRD4 | |
| SCHEMBL2293419 | 0.79 | HPGD (0.42) | RXRARXRBDRD2HRH4HRH1 | |
| SCHEMBL2293397 | 0.79 | HPGD (0.42) | RXRARXRBDRD2HRH4HRH1 | |
| SCHEMBL5182687 | 0.78 | MAPK1 (0.40) | MAPK1RXRARXRBDRD2DRD4 | |
| SCHEMBL5181121 | 0.76 | MAPK1 (0.39) | MAPK1RXRARXRBDRD2DRD4 | |
| SCHEMBL6407346 | 0.75 | NR4A2 (0.39) | MAPK1RXRARXRBDRD2HRH1 | |
| SCHEMBL2288734 | 0.75 | MAPK1 (0.56) | MAPK1RXRARXRBDRD2DRD4 | |
| SCHEMBL5182583 | 0.73 | MAPK1 (0.40) | MAPK1RXRARXRBDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684766-B1 | USE OF 3-AZA-1-OXA-DIBENZO i e,h /i AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-06-27 | — | — | EP | claimed |
| US-7232815-B2 | 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | GLAXOSMITHKLINE (HR) | 2007-06-19 | — | — | US | claimed |
| US-20070111990-A1 | 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-05-17 | — | — | US | claimed |
| EP-1492797-B1 | 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2006-03-15 | — | — | EP | claimed |
| US-20050148576-A1 | 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | claimed |
| US-20050130956-A1 | 1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | claimed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20110200618-A1 | ERBB4 INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-08-18 | — | — | US | disclosed |
| US-7232815-B2 | 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | GLAXOSMITHKLINE (HR) | 2007-06-19 | — | — | US | disclosed |
| US-20070111990-A1 | 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-05-17 | — | — | US | disclosed |
| EP-1492797-B1 | 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2006-03-15 | — | — | EP | disclosed |
| US-20050148576-A1 | 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | disclosed |
| US-20050130956-A1 | 1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | disclosed |
| EP-1492797-A1 | 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084964-A1 | 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF | PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148576-A1 | 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | TNF, IL1A, IL1B | MAPK1 379/4885RXRA 2092/4885RXRB 2214/4885 |
| US-20050130956-A1 | 1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | TNF, IL1A, IL1B | MAPK1 324/4885RXRA 1888/4885RXRB 2025/4885 |
| US-20070111990-A1 | 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | AZI2, DBH, BCHE | MAPK1 2679/4885RXRA 2049/4885RXRB 2018/4885 |
| US-20110200618-A1 | ERBB4 INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ERBB4, ERBB3, ERBB2 | MAPK1 585/4885RXRA 2231/4885RXRB 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.